Opipari Anthony W.
Known title: See RemarksCIK: 0002131341
Associated companies
Transaction History
| ODTX | ▼ Sell | Tax Withholding | 4 | $72 | 5/11/2026 | View on chart |
| ODTX | ▼ Sell | Other | 6,965 | — | 5/11/2026 | View on chart |
| ODTX | ▲ Buy | Option Exercise | 541 | — | 5/11/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026
Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026. Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.